Brief: Theratechnologies Announces Results From Trogarzo(Ibalizumab-Uiyk) Intramuscular Administration Study

Theratechnologies

13/10/2023 12:13

Oct 13 (Reuters) - Theratechnologies Inc  TH.TO :
    * THERATECHNOLOGIES ANNOUNCES RESULTS FROM TROGARZO
(IBALIZUMAB-UIYK) INTRAMUSCULAR ADMINISTRATION STUDY
    * THERATECHNOLOGIES - PRIMARY ENDPOINT MEASURING 90%
CONFIDENCE
INTERVAL OF RATIO OF IM INJECTION TO IV INFUSION DID NOT MEET
EQUIVALENCE LIMITS
    * THERATECHNOLOGIES INC -  VIRAL SUPPRESSION, WAS MAINTAINED
IN
ALL HIV-POSITIVE SUBJECTS THROUGHOUT IM PHASE AND OVERALL STUDY
    * THERATECHNOLOGIES-SUBJECTS RECEIVED IM MAINTENANCE DOSES
FOR 8
WEEKS OF TREATMENT & TOTAL OF 152 IM INJECTIONS ADMINISTERED,
THAT WERE WELL TOLERATED
    * THERATECHNOLOGIES- FDA CURRENTLY REVIEWING SUBMISSION FOR
LOADING DOSE OF TROGARZO(®) IV PUSH METHOD OF ADMINISTRATION,
DECISION EXPECTED MID-DECEMBER

Source text for Eikon:  ID:nGNX4ZGql2 
Further company coverage:  TH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))